These findings highlight TGF-β1 as a key mediator of AngII-induced cognitive deficits, beyond hypoperfusion, suggesting that targeting the TGF-β1/Smad2/3/Sp1 axis may offer therapeutic benefits for hypertension-related synaptic and cognitive dysfunction. This evidence concerns the gene SMAD2 and hypertensive disorder.